Identification of biorelevant dissolution media to assess biopharmaceutical performance of erlotinib formulation with enhanced bioavailability using physiologybased pharmacokinetic modeling. AJP [Internet]. 2022 Jun. 15 [cited 2026 Apr. 14];16(2). Available from: http://www.asiapharmaceutics.info/index.php/ajp/article/view/4389